2.43
0.04 (1.67%)
| Previous Close | 2.39 |
| Open | 2.39 |
| Volume | 7,721 |
| Avg. Volume (3M) | 13,993 |
| Market Cap | 10,933,569 |
| Price / Sales | 10.52 |
| Price / Book | 0.720 |
| 52 Weeks Range | |
| Earnings Date | 27 May 2026 |
| Profit Margin | -15.21% |
| Operating Margin (TTM) | -937.65% |
| Diluted EPS (TTM) | -6.00 |
| Quarterly Revenue Growth (YOY) | -96.30% |
| Total Debt/Equity (MRQ) | 65.87% |
| Current Ratio (MRQ) | 2.28 |
| Operating Cash Flow (TTM) | -32.35 M |
| Levered Free Cash Flow (TTM) | -19.19 M |
| Return on Assets (TTM) | -21.98% |
| Return on Equity (TTM) | -20.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BioLineRx Ltd. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.08% |
| % Held by Institutions | 0.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nemes Rush Group Llc | 31 Dec 2025 | 250 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |